Highlights Lexaria Bioscience Corp.

Equities

LEXX

US52886N4060

Market Closed - Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
2.64 ^USD	+0.76%		+1.93%	+111.20%

Jun. 18	Lexaria Bioscience Hires Contract Research Organization For 12-week Study	MT
Jun. 18	Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study	Jun. 18	CI
Lexaria Bioscience Corp. Announces Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study	Jun. 05	CI
Lexaria Bioscience Completes Dosing in Second Round of Semaglutide Formulations Human Pilot Study	Jun. 05	MT
Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise	May. 21	MT
Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study	May. 17	CI
Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study	May. 08	CI
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs	May. 06	CI
Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study	Apr. 16	MT
Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	Apr. 16	CI
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Apr. 09	CI
Lexaria Bioscience Corp. Receives New Patents in the Fields of Epilepsy and Anti-Viral Agents	Apr. 02	CI
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1	Mar. 05	CI
Lexaria Bioscience Corp. Signs Contracts to Begin Animal Study Well-A24-1	Mar. 04	CI
Lexaria Bioscience Corp. Announces 7% Weight Loss in Animals Supports in its Next 8-Week Animal Study	Mar. 04	CI
Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial	Mar. 01	CI
Lexaria Bioscience Corp. Submits Investigational New Drug Application	Jan. 30	CI
Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program	Jan. 16	CI
Lexaria Bioscience Corp. Reports Earnings Results for the First Quarter Ended November 30, 2023	Jan. 12	CI
Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream	Jan. 11	CI
Lexaria Bioscience Corp. Improves Delivery, Efficacy of Glp-1 Agonists Through Proprietary Drug-Delivery Platform	Jan. 09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lexaria Bioscience Corp.

Equities

LEXX

US52886N4060

Highlights

Filters